ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2020
Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer.
Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Expression of Claudin-18.2 in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Clinicopathologic Relevance of Claudin 18.2 Expression in Gastric Cancer: A Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Investigation of clinical application of claudin 18 isoform 2 in pancreatic ductal adenocarcinoma: A retrospective analysis of 302 chinese patients.Histology and histopathology · 2022Trial
- Claudin18.2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategies.Journal of hematology & oncology · 2026Review
- Antibody-drug conjugates in gastric cancer: from targeted cytotoxicity to immune modulation.Frontiers in immunology · 2026Review
- Claudin18.2 expression and its clinicopathological feature in adenocarcinoma from various parts.Journal of clinical pathology · 2025Article
- Article
- CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors.Cell reports. Medicine · 2024Article
- Antibody-drug conjugates in gastric cancer: from molecular landscape to clinical strategies.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024Review
- Progress of Clinical Studies Targeting Claudin18.2 for the Treatment of Gastric Cancer.Digestive diseases and sciences · 2024Review
- Article
- Construction of a Human Immune Library from Gallbladder Cancer Patients for the Single-Chain Fragment Variable (Antibodies (Basel, Switzerland) · 2024Article
- Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma.Current oncology (Toronto, Ont.) · 2024Review
- Expression and Targeted Application of Claudins Family in Hepatobiliary and Pancreatic Diseases.Journal of hepatocellular carcinoma · 2024Review
- Dark horse target Claudin18.2 opens new battlefield for pancreatic cancer.Frontiers in oncology · 2024Review
- Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer.Scientific reports · 2023Article
- Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging.Biomedicines · 2023Review
- Targeting CD44 Variant 5 with an Antibody-Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma.Cancer research · 2023Article
- First-in-human CLDN18.2 functional diagnostic pet imaging of digestive system neoplasms enables whole-body target mapping and lesion detection.European journal of nuclear medicine and molecular imaging · 2023Article
- Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors.Journal of pharmaceutical analysis · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Claudin 18.2 (CLDN18.2) is a tight-junction protein. CLDN18.2-targeting strategy has cut a striking figure in CLDN18.2 positive patients with advanced gastric cancer. Zolbetuximab, the CLDN18.2 antibody, obtained a better clinical benefit in patients compared with the controlled. In phase II trials, combination treatment of epirubicin, oxaliplatin and capecitabine (EOX) + zolbetuximab achieved the optimal effects of overall survival which extended to 13.2 months with tolerable safety events, indicating its greater potential playing the second promising target in gastric cancer. This review will reveal the definitive clinical benefit CLDN18.2-targeting therapies have achieved and update the highlighting development (like chimeric antigen receptor T-cell immunotherapy) to CLDN18.2 positive patients. We then focus on 10 questions arisen from recent progress and anticipate to provide a future perspective for novel cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.